Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome

OBJECTIVES: Mutations affecting the TMEM173 gene cause STING-associated vasculopathy with onset in infancy (SAVI). No standard immunosuppressive treatment approach is able to control disease progression in patients with SAVI. We studied the efficacy and safety of targeting type I IFN signaling with...

Descripción completa

Detalles Bibliográficos
Autores principales: Volpi, Stefano, Insalaco, Antonella, Caorsi, Roberta, Santori, Elettra, Messia, Virginia, Sacco, Oliviero, Terheggen-Lagro, Suzanne, Cardinale, Fabio, Scarselli, Alessia, Pastorino, Claudia, Moneta, Gianmarco, Cangemi, Giuliana, Passarelli, Chiara, Ricci, Margherita, Girosi, Donata, Derchi, Maria, Bocca, Paola, Diociaiuti, Andrea, El Hachem, May, Cancrini, Caterina, Tomà, Paolo, Granata, Claudio, Ravelli, Angelo, Candotti, Fabio, Picco, Paolo, DeBenedetti, Fabrizio, Gattorno, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086512/
https://www.ncbi.nlm.nih.gov/pubmed/31144250
http://dx.doi.org/10.1007/s10875-019-00645-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086512/
https://www.ncbi.nlm.nih.gov/pubmed/31144250
http://dx.doi.org/10.1007/s10875-019-00645-0

Ejemplares similares